CS
TGTX icon

Credit Suisse’s TG Therapeutics TGTX Stock Holding History

Credit Suisse’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,200
Closed -$230K – 4140
2018
Q1 		$230K Buy
+16,200
New +$207K ﹤0.01% 3667
2017
Q4 		– Sell
-50,000
Closed -$593K – 4191
2017
Q3 		$593K Buy
+50,000
New +$570K ﹤0.01% 3444

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Suisse's TGTX Position: Q1 2024 in Review

Credit Suisse increased its TG Therapeutics (TGTX) stake by 0.41% in Q1 2024, buying an estimated $12.1K and bringing the position to 186,299 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1640.

Credit Suisse first reported a position in TGTX in Q4 2013 and has held it in 41 quarters since. The position peaked at $18.4M in Q1 2021. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Credit Suisse held 186,299 shares of TG Therapeutics worth $2.83M as of Q1 2024.
  • Credit Suisse bought 758 TG Therapeutics shares in Q1 2024, an estimated $12.1K.
  • TG Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1640 holding.
  • Credit Suisse first reported a position in TG Therapeutics in Q4 2013 and has held it in 41 quarters since.
  • Credit Suisse's TG Therapeutics position peaked at $18.4M in Q1 2021.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.